On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares. That is a striking move from a company that lost money in the second quarter of 2025. Here is what stands behind the announcement, and what the fine print does and does…
